Healthcare - Press Releases

Company to Participate in Upcoming Conferences

A case study on how a mid-sized pharmaceutical company collaborated with DelveInsight to expand its asset portfolio in the Atrial Fibrillation space. DelveInsight conducted comprehensive asset prioritization, identifying the most promising Phase II therapeutic candidates for licensing opportunities. This evidence-based approach helped the client strategically align the clinical trial pipeline with growth objectives, ensuring a competitive edge in the market.

AUSTIN, Texas, Jan. 27, 2025 /PRNewswire/ --In response to a devastating start to the new year with wildfires continuing to advance through the greater Los Angeles area, Pet King Brands, leader of the veterinarian-recommended ZYMOX and Oratene pet health products, provides monetary and product donations to organizations providing relief to animals in need.

Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination and Support for Caregivers

El modelo Guiding an Improved Dementia Experience (GUIDE) tiene como objetivo aumentar la coordinacin de la atencin y el apoyo a los cuidadores

SANTA MONICA, Calif., Jan. 27, 2025 /PRNewswire/ -- In his new book - Longevity Guidebook: How to Slow, Stop, and Reverse Aging, and NOT DIE from Something Stupid - New York Times bestselling author, futurist and entrepreneur, Peter H. Diamandis, MD, describes the longevity revolution racing our way at the convergence of AI, genomics, and cellular medicine.

Event will showcase results of Company's pivotal PRIME study and include the principal investigator

LONG BEACH, Calif., Jan. 27, 2025 /PRNewswire/ -- Anivive Lifesciences, a software-driven pet health company, is pleased to announce it has secured $20MM in funding from Leonid Capital Partners ("Leonid"). Leonid is a leading investment firm focused on high-growth technology companies working in the national security industry.

SUZHOU, China, Jan. 26, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced a strategic commercialization partnership with SteinCares, a leading pharmaceutical company with over 40 years of experience anda strong presence in Latin America. Under this agreement, SteinCares will gain the commercialization rights for sugemalimab in 10 LATAM countries, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala and Ecuador.

SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Robbins LLPinforms investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024. ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The Company's lead product candidate was masofaniten, which was in clinical trial in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.

Trend Predictions Unveiled: From Beauty Voyagers to Nano Neighborhoods

STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly,SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of units that was announced on November 12, 2024. Following the completed recalculation, SciBase can confirm that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share, remains unchanged. Thus, one (1) warrant of series TO 2 entitles the holder to subscribe for one (1) share at a subscription price of SEK 0.42, in accordance with the previously communicated terms and conditions for the warrants.

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The globalnitrile gloves marketsize is estimated to grow by USD 3.54 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.8% during the forecast period. Rising concerns about hygiene and safety regarding healthcare-associated infectionsis driving market growth,with a trend towardsincreasing preference for biodegradable and powder-free nitrile gloves. However,volatile raw material prices and currency fluctuations poses a challenge. Key market players include 3M Co., Adenna LLC, AMMEX Corp., Ansell Ltd., Atlantic Safety Products Inc., Cardinal Health Inc., Diamond Gloves, Dolphin Products Inc., Dynarex Corp., Globus Shetland Ltd., Hartalega Holdings Berhad, Hebei Aihede Protective Products Co. Ltd., Honeywell International Inc., Hongray Group, HYGECO International SA, Just Gloves, Kanam Latex Industries Pvt. Ltd, Kimberly Clark Corp., Kossan Rubber Industries Bhd, and McKesson Corp..

A mind-numbing bore fest or a wake-up call? The nine-hour runtime exposes the staggering impact of smartphone overuse on 84% of teens, highlighting issues such as ADHD, depression, and more.This film mirrors the average time teenagers spend doom-scrolling, shedding light on the urgent need for change.

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ --On the eve of theArab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration.

NEW YORK, Jan. 26, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The globalmedical gas blenders marketsize is estimated to grow by USD 582 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.42% during the forecast period. Growing geriatric population and rising prevalence of chronic diseasesis driving market growth,with a trend towardsincreasing use of respiratory gas blenders in NICUs. However,stringent regulations on design and manufacturing of medical gas blenders poses a challenge. Key market players include Medin Medical Innovations GmbH, HEYER Medical AG, EKU Electronics, Armstrong Medical, Becton, Dickinson and Company, Farstar (Wuxi) Medical Equipment, Dameca, Flow-meter S.p.A, Smiths Medical, Heyer Aerotech GmbH, DEHAS Medical Systems GmbH, ESAB Corp., Genstar Technologies Co. Inc., Guangdong Pigeon Medical Apparatus Co. Ltd., HVS Oliver Hornla GmbH and Co. KG, Inspiration Healthcare Group Plc., MCQ Instruments, Ningbo David Medical Device Co. Ltd., Precision Medical Inc., S S Technomed P Ltd.

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global healthcare services marketsize is estimated to grow by USD 6.26 trillion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.73% during the forecast period. Increasing prevalence of chronic diseasesis driving market growth,with a trend towardsrise in adoption of telemedicine in healthcare sector. However,increasing healthcare costs poses a challenge. Key market players include Apollo Hospitals Enterprise Ltd, athenahealth Inc., Community Health Systems Inc., CVS Health Corp., DaVita Inc., Dr Lal PathLabs Ltd., Expedient Healthcare Marketing Pvt. Ltd., Fresenius Medical Care AG and Co. KGaA, Genesis Healthcare Inc., iHealth Labs Inc., Max Healthcare Institute Ltd, Mayo Foundation for Medical Education and Research, McKesson Corp., OMH HealthEdge Holdings LLC, Optum Inc., Quest Diagnostics Inc., Sonic Healthcare Ltd., Universal Health Services Inc., and West Suffolk NHS Foundation Trust.

SACRAMENTO, Calif., Jan. 24, 2025 /PRNewswire/ --The California Fire Foundation, in partnership with GovernorGavin Newsom, have announced "California Rises," a bold new phase of wildfire recovery and resilience, providing relief and grants to communities devastated by catastrophic wildfires in the Los Angeles-area.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis. The strategic combination of drugs such as gumokimab and ebronucimab (PCSK9) to address the differentiated treatment needs of psoriasis has further enhanced the company's overall product synergy in the autoimmune disease field.

TAICHUNG, Jan. 26, 2025 /PRNewswire/ -- Since its inception in 2016, the China Medical University Hospital (CMUH) International Center has been dedicated to providing world-class healthcare to the people of Guam, delivering nearly 900 services to date. This partnership has extended beyond medical care, with CMUH's significant contributions during the COVID-19 pandemic. In 2020, the hospital worked closely with Taiwan's Ministry of Foreign Affairs to donate 200,000 face masks to Guam, a gesture for which Guam's government later issued a resolution of gratitude. Additionally, CMUH organized "humanitarian healthcare flights" for the people of Guam, further solidifying ties and contributing to the sister-city relationship between Taichung and Guam established in 2022. These efforts exemplify Taiwan's commitment to supporting global health, demonstrating the power of "medical diplomacy."

STOCKHOLM, Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in the U.S. (early Alzheimer's disease). This approval means that patients who have completed the biweekly initiation phase of 18 months have the option to transition to a once every four weeks 10 mg/kg dosing regimen.

STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in the U.S. (early Alzheimer's disease). This approval means that patients who have completed the biweekly initiation phase of 18 months have the option to transition to a once every four weeks 10 mg/kg dosing regimen.